1.Increase of red blood cell's mean corpuscular volume in the elderly normal population of Korea.
Soo Jung JE ; Cheolwon SUH ; Hyun Sook CHI
Korean Journal of Hematology 1992;27(2):227-231
No abstract available.
Aged*
;
Erythrocyte Indices*
;
Humans
;
Korea*
2.Non-gastric Marginal Zone B-cell Lymphoma in Korea: Clinical Features, Treatment, and Prognostic Factors.
The Korean Journal of Internal Medicine 2010;25(3):227-236
Marginal zone B-cell lymphoma (MZL) is the second most common subtype of non-Hodgkin's lymphoma in Korea (17.3%). Mucosa-associated lymphoid tissue (MALT) can develop in almost any organ as a result of exposure to a persistent stimulus, such as chronic infection or certain autoimmune processes. Under conditions of prolonged lymphoid proliferation, a malignant clone may emerge, which is followed by the development of a MALT lymphoma. Whereas MALT lymphoma of the stomach is the most common and the most extensively studied, we focus on non-gastric MZL studies conducted in Korea that highlight the most recent advances with respect to MZL definition, etiology, clinical characteristics, natural history, treatment approaches, outcomes, and prognostic factors. Moreover, we discuss current organ-specific considerations and controversies, and identify areas for future research.
Humans
;
Korea
;
Lymphoma, B-Cell, Marginal Zone/*diagnosis/*therapy
;
Neoplasm Staging
;
Organ Specificity
;
Prognosis
;
Splenic Neoplasms/diagnosis/therapy
3.Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor.
Changhoon YOO ; Dok Hyun YOON ; Cheolwon SUH
Blood Research 2014;49(3):148-153
Beta-2 microglobulin is synthesized in all nucleated cells and forms the light chain subunit of the major histocompatibility complex class I antigen. Despite its potential role as a convenient and non-invasive prognostic indicator in malignant lymphomas, the influence of serum beta2 microglobulin is currently underestimated, and therapeutic decision making is rarely affected by this marker. Recent studies that included relatively large numbers of patients with specific histologic subtypes showed that serum beta2 microglobulin is a potent prognostic marker in malignant lymphomas. In follicular lymphoma, this effort led to the incorporation of serum beta2 microglobulin as an indicator in a new prognostic model. In this review, we summarize the current evidence supporting the role of serum beta2 microglobulin as a prognostic factor in patients with malignant lymphoma and discuss perspectives for future investigations.
Decision Making
;
Humans
;
Lymphoma*
;
Lymphoma, Follicular
;
Major Histocompatibility Complex
4.The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective.
Cheolwon SUH ; Byeong Bae PARK ; Won Seog KIM
Blood Research 2017;52(1):3-6
No abstract available.
Lymphoma*
5.Relevance of prognostic index with β2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era.
Jihoon KANG ; Shinkyo YOON ; Cheolwon SUH
Blood Research 2017;52(4):276-284
BACKGROUND: The International Prognostic Index (IPI) has been a useful tool for predicting the prognosis of aggressive non-Hodgkin lymphoma in the last 20 years. Herein, we aimed to develop a new prognostic model for diffuse large B-cell lymphoma (DLBCL) in the rituximab era. METHODS: Between March 2004 and June 2012, patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy regimen were identified in the database of the Asan Medical Center (AMC) Lymphoma Registry. The primary and secondary endpoints were a new prognostic index for DLBCL and validation of the National Comprehensive Cancer Network-International Prognostic Index in our cohort, respectively. RESULTS: The AMC cohort comprised 621 patients. The median follow-up duration was 43.3 months (range, 6.2–122.5 mo). Univariate analysis revealed that age (≤60 vs. >60 yr), lactate dehydrogenase (LDH; within normal vs. increased), Eastern Cooperative Oncology Group performance status (ECOG PS; 0 or 1 vs. ≥2), advanced stage (Ann Arbor stage I/II vs. III/IV), extra-nodal involvement (≤1 vs. >1), B symptoms (no vs. yes), and beta-2 microglobulin (β2MG, ≤2.5 vs. >2.5) can be used to predict overall survival (OS). In multivariate analysis, only age, LDH, ECOG performance status, and β2MG were significantly associated with OS, and we developed a new prognostic model with these 4 factors. The new prognostic model showed better discriminative power compared with the classic IPI. CONCLUSION: Our new prognostic index model for DLBCL in the rituximab era has good discriminative power and is convenient to use.
B-Lymphocytes*
;
Chungcheongnam-do
;
Cohort Studies
;
Cyclophosphamide
;
Doxorubicin
;
Drug Therapy
;
Follow-Up Studies
;
Humans
;
L-Lactate Dehydrogenase
;
Lymphoma
;
Lymphoma, B-Cell*
;
Lymphoma, Non-Hodgkin
;
Multivariate Analysis
;
Prednisolone
;
Prognosis
;
Rituximab*
;
Vincristine
6.Clinical features and survival outcomes of patients with lymphoplasmacytic lymphoma, including non-IgM type, in Korea: a single-center experience.
Jihoon KANG ; Jung Yong HONG ; Cheolwon SUH
Blood Research 2018;53(3):189-197
BACKGROUND: The incidence of lymphoplasmacytic lymphoma (LPL) is lower in Asian than in Western populations. Few studies have described the clinical features and treatment outcomes of patients with LPL, including non-IgM LPL, in East Asia. METHODS: We retrospectively analyzed patients diagnosed with LPL at Asan Medical Center between January 2001 and March 2016. We evaluated the clinical features and survival outcomes of patients with LPL and non-IgM LPL and compared these data with those of patients with LPL/Waldenström's macroglobulinemia (WM). RESULTS: The median age at diagnosis of patients with LPL was 61.5 years (range, 34–77 yr); most patients were male (91%). Approximately three-quarters of the 22 patients with LPL were in the low or intermediate risk groups according to the International Prognostic Scoring System for Waldenström's Macroglobulinemia classification. The median follow-up duration was 75 months [95% confidence interval (CI), 48–102 mo], and the median overall survival (OS) was 81 months (95% CI, 0–167 mo). The number of patients in the non-IgM LPL group who exhibited extramedullary involvement was higher than in the LPL/WM group. OS of the LPL/WM group was improved compared with that of the non-IgM LPL group [median not reached vs. 10.0 mo (95% CI, 0–36.7); P=0.05]. CONCLUSION: We present a single-center experience of 22 patients with LPL, including a non-IgM cohort, in Korea. The treatment of non-IgM LPL was heterogeneous, and patients with non-IgM LPL showed a higher 5-year mortality rate and more adverse prognostic factors than those with LPL/WM.
Asian Continental Ancestry Group
;
Chungcheongnam-do
;
Classification
;
Cohort Studies
;
Diagnosis
;
Far East
;
Follow-Up Studies
;
Humans
;
Incidence
;
Korea*
;
Lymphoma*
;
Male
;
Mortality
;
Retrospective Studies
;
Waldenstrom Macroglobulinemia
7.Clinical Characteristics of Monomorphic Post-transplant Lymphoproliferative Disorders.
Jung Hye CHOI ; Byeong Bae PARK ; Cheolwon SUH ; Jong Ho WON ; Won Sik LEE ; Ho Jin SHIN
Journal of Korean Medical Science 2010;25(4):523-526
Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group of lymphoproliferative disorders associated with immunosuppression and Epstein-Barr virus infection. PTLD is classified into three major categories: early lesions, polymorphic PTLD, and monomorphic PTLD. The majority of monomorphic PTLD cases are non-Hodgkin's lymphoma of B-cell origin. This retrospective study was conducted to investigate the incidence, clinical manifestation, treatment, and outcomes of monomorphic PTLD among 5,817 recipients of solid organ or allogeneic hematopoietic stem cell transplantation from five institutions. Fourteen patients with monomorphic PTLD were identified (male:female 11:3; median age 42.6 yr, range 24-60). The overall incidence rate was 0.24%. The most common disease type was diffuse large B cell lymphoma (n=7). The median time between the transplant and diagnosis of PTLD was 85.8 months. However, all cases of PTLD after allogeneic hematopoietic stem cell transplantation occurred within 1 yr after transplantation. Ten of the 14 patients had EBV-positive tumor. Fourteen patients received combination systemic chemotherapy and four patients were treated with radiation therapy. Ten patients achieved a complete response (CR) and two patients a partial response (PR). The median follow-up period for surviving patients was 36.6 months. Nine patients remain alive (eight CR, one PR). Nine of 11 solid organ transplantations preserved graft function. The present study indicates a lower incidence rate and a longer median time before the development of PTLD than those of previous reports. Careful monitoring was needed after allogeneic hematopoietic stem cell transplantation for PTLD.
Adult
;
Epstein-Barr Virus Infections/complications/immunology
;
Female
;
Herpesvirus 4, Human
;
Humans
;
Lymphoproliferative Disorders/classification/etiology/immunology/*physiopathology
;
Male
;
Middle Aged
;
Retrospective Studies
;
Survival Rate
;
Transplantation, Homologous/*adverse effects/immunology
;
Treatment Outcome
;
Young Adult
8.GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression.
Young Wha KOH ; Jae Ho HAN ; Seong Yong PARK ; Dok Hyun YOON ; Cheolwon SUH ; Jooryung HUH
Journal of Pathology and Translational Medicine 2017;51(2):152-158
BACKGROUND: Glucose transporter type 1 (GLUT1) expression is linked to glucose metabolism and tissue hypoxia. A recent study reported that GLUT1 was significantly associated with programmed death ligand 1 (PD-L1) as a therapeutic target in relapsed or refractory classical Hodgkin's lymphoma (cHL). The purpose of this study was to measure the expression of GLUT1 and assess its prognostic significance and potential relationships with PD-L1, programmed death ligand 2 (PD-L2), and programmed death-1 (PD-1) expressions in cHL. METHODS: Diagnostic tissues from 125 patients with cHL treated with doxorubicin, bleomycin, vinblastine, and dacarbazine were evaluated retrospectively via immunohistochemical analysis of GLUT1, PD-L1, PD-L2, and PD-1 expression. RESULTS: The median follow-up time was 4.83 years (range, 0.08 to 17.33 years). GLUT1, PD-L1, PD-L2, and PD-1 were expressed in 44.8%, 63.2%, 9.6%, and 13.6% of the specimens, respectively. Positive correlations were found between GLUT1 and PD-L1 expression (p = .004) and between GLUT1 and PD-L2 expression (p = .031). GLUT1 expression in Hodgkin/Reed-Sternberg (HRS) cells was not associated with overall survival or event-free survival (EFS) in the entire cohort (p = .299 and p = .143, respectively). A subgroup analysis according to the Ann Arbor stage illustrated that GLUT1 expression in HRS cells was associated with better EFS in advanced-stage disease (p = .029). A multivariate analysis identified GLUT1 as a marginally significant prognostic factor for EFS (p = .068). CONCLUSIONS: This study suggests that GLUT1 expression is associated with better clinical outcomes in advanced-stage cHL and is significantly associated with PD-L1 and PD-L2 expressions.
9.Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement.
Ock Bae KO ; Geundoo JANG ; Shin KIM ; Jooryung HUH ; Cheolwon SUH
The Korean Journal of Internal Medicine 2008;23(4):182-190
BACKGROUND/AIMS: Diffuse large B-cell lymphoma (DLBCL) in Koreans is frequently accompanied by extranodal (EN) disease at the time of autologous stem cell transplantation (ASCT). We sought to determine whether high EN involvement affected survival following ASCT in Koreans. METHODS: We reviewed 27 patients who had DLBCL with residual disease at ASCT: 13 with residual disease at nodal site(s) only and 14 with nodal and EN disease. RESULTS: Univariate analysis showed that disease status, lactate dehydrogenase (LDH), and performance status at ASCT were predictors of survival following ASCT. The number of EN sites, as categorized by the International Prognostic Index system, had no prognostic significance. When EN involvement at ASCT was classified as negative or positive, the 2-year overall survival for the negative group was 64%, significantly better than the 14% for the positive group (p=0.021), and the event-free survival for the negative group was 62%, significantly better than the 14% for the positive group (p=0.02). CONCLUSIONS: Patients who had DLBCL with residual EN involvement at ASCT showed worse outcomes following ASCT compared to those without EN disease.
Adolescent
;
Adult
;
Aged
;
Cohort Studies
;
Female
;
Humans
;
Korea
;
Lymphoma, Large B-Cell, Diffuse/mortality/*pathology/*therapy
;
Male
;
Middle Aged
;
Neoplasm, Residual
;
Retrospective Studies
;
*Stem Cell Transplantation
;
Survival Rate
;
Treatment Outcome
;
Young Adult
10.Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis.
Jin Young HUH ; Seyoung SEO ; Cheolwon SUH ; Jooryung HUH ; Dok Hyun YOON ; Jae Joong KIM
Blood Research 2017;52(3):221-224
No abstract available.
Amyloidosis*
;
Heart*
;
Stem Cell Transplantation*
;
Stem Cells*